|
1
|
Tausch E, Schneider C, Yosifov D, Robrecht S, Zhang C, Al‐Sawaf O, Eichhorst B, Fink A, Bloehdorn J, Kreuzer K, Tandon M, Jiang Y, Kim SY, Porro Lura M, Döhner H, Fischer K, Hallek M, Stilgenbauer S. GENETIC MARKERS AND OUTCOME WITH FRONT LINE OBINUTUZUMAB PLUS EITHER CHLORAMBUCIL OR VENETOCLAX ‐ UPDATED ANALYSIS OF THE CLL14 TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.30_2879] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- E Tausch
- Ulm University Department of internal medicine 3 Ulm Germany
| | - C Schneider
- Ulm University Department of internal medicine 3 Ulm Germany
| | - D Yosifov
- Ulm University Department of internal medicine 3 Ulm Germany
| | - S Robrecht
- University Hospital Cologne Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf Cologne Germany
| | - C Zhang
- University Hospital Cologne Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf Cologne Germany
| | - O Al‐Sawaf
- University Hospital Cologne Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf Cologne Germany
| | - B Eichhorst
- University Hospital Cologne Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf Cologne Germany
| | - A.‐M Fink
- University Hospital Cologne Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf Cologne Germany
| | - J Bloehdorn
- Ulm University Department of internal medicine 3 Ulm Germany
| | - K.‐A Kreuzer
- University Hospital Cologne Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf Cologne Germany
| | - M Tandon
- Roche Products Limited Clinical development Welwyn Garden City UK
| | - Y Jiang
- Genentech, Hematology South San Francisco USA
| | - S. Y Kim
- AbbVie, Medical, North Chicago United States of America
| | | | - H Döhner
- Ulm University Department of internal medicine 3 Ulm Germany
| | - K Fischer
- Ulm University Department of internal medicine 3 Ulm Germany
| | - M Hallek
- University Hospital Cologne Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf Cologne Germany
| | - S Stilgenbauer
- Ulm University Department of internal medicine 3 Ulm Germany
| |
Collapse
|
|
2
|
Al‐Sawaf O, Zhang C, Robrecht S, Tandon M, Panchal A, Fink A, Tausch E, Ritgen M, Kreuzer K, Kim S, Wendtner C, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K. VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4‐YEAR FOLLOW‐UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.49_2880] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- O. Al‐Sawaf
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - C. Zhang
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - S. Robrecht
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - M. Tandon
- Roche Products Limited Welwyn Garden City UK
| | - A. Panchal
- Roche Products Limited Welwyn Garden City UK
| | - A.‐M. Fink
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - E. Tausch
- University Hospital Ulm Department III of Internal Medicine Ulm Germany
| | - M. Ritgen
- University of Schleswig‐Holstein Department II of Internal Medicine Kiel Germany
| | - K.‐A. Kreuzer
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | | | - C. Wendtner
- Klinikum Schwabing Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine Munich Germany
| | - B. Eichhorst
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - S. Stilgenbauer
- University Hospital Ulm Department III of Internal Medicine Ulm Germany
| | | | - M. Hallek
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - K. Fischer
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| |
Collapse
|
|
3
|
Al‐Sawaf O, Esfahani MS, Zhang C, Tausch E, Schilhabel A, Eichhorst B, Stilgenbauer S, Hallek M, Alizadeh AA, Kurtz DM, Fischer K. A CONTINUOUS INDIVIDUALIZED RISK INDEX FOR REFINED OUTCOME PREDICTION AFTER TARGETED THERAPY FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CIRI‐CLL). Hematol Oncol 2021. [DOI: 10.1002/hon.51_2880] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- O. Al‐Sawaf
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - M. S. Esfahani
- Stanford University Divisions of Oncology & Hematology, Department of Medicine Stanford USA
| | - C. Zhang
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - E. Tausch
- University Hospital Ulm Department III of Internal Medicine Ulm Germany
| | - A. Schilhabel
- University of Schleswig‐Holstein Department II of Internal Medicine Kiel Germany
| | - B. Eichhorst
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - S. Stilgenbauer
- University Hospital Ulm Department III of Internal Medicine Ulm Germany
| | - M. Hallek
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - A. A. Alizadeh
- Stanford University Divisions of Oncology & Hematology, Department of Medicine Stanford USA
| | - D. M. Kurtz
- Stanford University Divisions of Oncology & Hematology, Department of Medicine Stanford USA
| | - K. Fischer
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| |
Collapse
|
|
4
|
Al‐Sawaf O, Zhang C, Lu T, Liao MZ, Panchal A, Robrecht S, Ching T, Tandon M, Fink A, Tausch E, Ritgen M, Böttcher S, Kreuzer K, Kim S, Miles D, Wendtner C, Stilgenbauer S, Eichhorst B, Jiang Y, Hallek M, Fischer K. VENETOCLAX‐OBINUTUZUMAB MODULATES CLONAL GROWTH: RESULTS OF A POPULATION‐BASED MINIMAL RESIDUAL DISEASE MODEL FROM THE RANDOMIZED CLL14 STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.31_2879] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- O Al‐Sawaf
- University Hospital of Cologne Department I of Internal Medicine, Cologne Germany
| | - C Zhang
- University Hospital of Cologne Department I of Internal Medicine, Cologne Germany
| | - T Lu
- Genentec Inc San Francisco USA
| | | | - A Panchal
- Roche Products Limited Welwyn Garden City UK
| | - S Robrecht
- University Hospital of Cologne Department I of Internal Medicine, Cologne Germany
| | - T Ching
- Adaptive Biotechnologies Corp Seattle USA
| | - M Tandon
- Roche Products Limited Welwyn Garden City UK
| | - A.‐M Fink
- University Hospital of Cologne Department I of Internal Medicine, Cologne Germany
| | - E Tausch
- University Hospital Ulm Department III of Internal Medicine Ulm Germany
| | - M Ritgen
- University of Schleswig‐Holstein Department II of Internal Medicine Kiel Germany
| | - S Böttcher
- University Hospital Rostock Department III of Internal Medicine, Rostock Germany
| | - K.‐A Kreuzer
- University Hospital of Cologne Department I of Internal Medicine, Cologne Germany
| | | | | | - C Wendtner
- Klinikum Schwabing Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine Munich Germany
| | - S Stilgenbauer
- University Hospital Ulm Department III of Internal Medicine Ulm Germany
| | - B Eichhorst
- University Hospital of Cologne Department I of Internal Medicine, Cologne Germany
| | - Y Jiang
- Genentec Inc San Francisco USA
| | - M Hallek
- University Hospital of Cologne Department I of Internal Medicine, Cologne Germany
| | - K Fischer
- University Hospital of Cologne Department I of Internal Medicine, Cologne Germany
| |
Collapse
|
|
5
|
Al‐Sawaf O, Robrecht S, Stumpf J, Fink A, Ritgen M, Johansson P, Tausch E, Hoechstetter M, Staber P, Jäger U, Niemann CU, Pallasch C, Kreuzer K, Stilgenbauer S, Fischer K, Wendtner C, Hallek M, Eichhorst B. THE CLL‐RT1 TRIAL: A MULTICENTER PHASE‐2 TRIAL OF ZANUBRUTINIB, A BTK INHIBITOR, PLUS TISLELIZUMAB, A PD‐1 INHIBITOR, FOR PATIENTS WITH RICHTER TRANSFORMATION. Hematol Oncol 2021. [DOI: 10.1002/hon.161_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- O. Al‐Sawaf
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - S. Robrecht
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - J. Stumpf
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - A.‐M. Fink
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - M. Ritgen
- University of Schleswig‐Holstein Department II of Internal Medicine Kiel Germany
| | - P. Johansson
- University Hospital Essen Clinic for Hematology Essen Germany
| | - E. Tausch
- University Hospital Ulm Department III of Internal Medicine Ulm Germany
| | - M. Hoechstetter
- Klinikum Schwabing Department of Hematology Oncology Immunology Palliative Care Infectious Diseases and Tropical Medicine Munich Germany
| | - P. Staber
- Medical University of Vienna Department of Medicine I Division of Hematology & Hemostaseology Vienna Austria
| | - U. Jäger
- Medical University of Vienna Department of Medicine I Division of Hematology & Hemostaseology Vienna Austria
| | - C. U. Niemann
- Department of Haematology Rigshospitalet and Department of Clinical Medicine University of Copenhagen, Denmark Copenhagen Denmark
| | - C. Pallasch
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - K.‐A. Kreuzer
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - S. Stilgenbauer
- University Hospital Ulm Department III of Internal Medicine Ulm Germany
| | - K. Fischer
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - C. Wendtner
- Klinikum Schwabing Department of Hematology Oncology Immunology Palliative Care Infectious Diseases and Tropical Medicine Munich Germany
| | - M. Hallek
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| | - B. Eichhorst
- University Hospital of Cologne Department I of Internal Medicine Cologne Germany
| |
Collapse
|